Gatipotuzumab - Glycotope

Drug Profile

Gatipotuzumab - Glycotope

Alternative Names: Anti-TA-MUC1 monoclonal antibody - Glycotope; GlycoOptimised IgG1 antibody - Glycotope; GT-MAB 2.5-GEX™; PankoMab; PankoMab-GEX; Trifunctional antibody - Glycotope

Latest Information Update: 01 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NEMOD Biotherapeutics [CEASED]
  • Developer Glycotope
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 30 Jul 2018 Daiichi Sankyo enters into licensing agreement with Glycotope for gatipotuzumab antibody drug conjugate
  • 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours in Switzerland (IV, Infusion)
  • 02 Nov 2017 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Spain, Germany (IV) (NCT03360734)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top